Search

Your search keyword '"Almirante Gragera, B."' showing total 24 results
Start Over Author "Almirante Gragera, B."
24 results on '"Almirante Gragera, B."'

8. Nosocomial infections. Evaluation of the objectives of the Health Plan for Catalonia for the year 2000 | Infecciones nosocomiales. Evaluación de los objetivos del Plan de Salud de Cataluña para el año 2000

Author

Vaqué, J., Domínguez, Á, Rosselló, J., Hermosilla, E., Gabari, M., Gavaldà, L., Barrio, J., Trilla, A., Javaloyas, M., Olona, M., Izquierdo, C., Cardeñosa, N., Rosselló Urgell, J., Magda Campins Martí, Armadans Gil, L., Palomar Martínez, M., Almirante Gragera, B., Del Valle Ortiz, O., Planes Reig, A., Gabari Machín, M., Trilla García, A., Bayas García, J. M., Prat Marín, A., Barrio Medrano, J. L., Fernández Dorado, F., Mateu Ruiz, C., Garcés Jarque, J. M., Pi-Sunyer, M. T., Tuyet Huch, J., Salvia Roigés, M. D., San Juan Martínez, N., Camps I Salat, R., Rossell Abaurrea, F., Latorre Otín, C., Martínez Montauti, J., García, I., González Vázquez, M., Javaloyas Morlius, M., Casas García, I., Esteve Pardo, M. G., Espí Boscà, A., Fort Almiñana, I., Nonell Gregori, F., Espejo Arenas, E., Serrate San Miguel, G., Gasós Rubio, M. A., Corcoy Grabalosa, F., Force Sanmartín, Ll, Priu Baixeras, R., Pérez Vidal, R., Dorca Badía, E., Marcos Bruguera, J. M., Esquius Ausió, M., Báguena Escolano, F., García Flores, A., Hernández Hernández, J. A., Cuquet Pedragosa, J., Durán Bellido, P., Ariño Blasco, S., Sierra Cardillach, J., Vilaró I Pujal, J., Lizándara Enrich, A. M., Pascal Calabuig, B., Vilamala Bastard, A., Gavaldà Mestre, L., Grané Alsina, J., Bisbe Company, J., García Tejero, C., Matesanz Borrás, J., Serna Marced, A., Nogués Biau, A., Manonelles Fernández, A., Montardit Bertral, I., Raga Llusià, X., Calbet Vidal, J. M., Ballester, F., Sans Mateu, T., and Rebull Fatsini, J.

10. Programa d’optimització d’antibiòtics: infeccions del tracte urinari en adults

Author

Almirante Gragera, Benito, Álvarez-Martins, Marlene, Ardanuy, Camen, Bonet Monné, Sara, Canadell Vilarrasa, Laura, Cano Marron, Manuel, Carrasco Fons, Natàlia, Casanovas Marfà, Maria del Mar, Chamarro Martí, Elena, Cots, Josep M., Fernandez Polo, Aurora, García González, Mercè, García Pardo, Graciano, García Vicente, Juan A., Giménez-Pérez, Montserrat, Gomez, Frederic, Gratacós Santanach, Laura, Gudiol, Carlota, Llopis, Maria A., Julián-Ávila, Esther, Larrosa Escartin, María Nieves, Lérida Urteaga, Ana, Martín González, Lidia, Mòdol-Deltell, Josep M., Molina Lázaro, Amparo, Motjé Casas, Montserrat, Oms Arias, Míriam, Padullés, Ariadna, Pérez-Moreno, Mar Olga, Pujol, Miquel, Salgado Serrano, Xavier, Troncoso Mariño, Amelia, Jover-Saenz, Alfredo, [Almirante Gragera B] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. [Álvarez Martins M] Servei de Farmàcia, Hospital Universitari Germans Trias i Pujol, Institut Català de la Salut (ICS), Generalitat de Catalunya, Badalona, Spain. [Ardanuy Tisaire C] Servei de Microbiologia, Hospital Universitari de Bellvitge, Institut Català de la Salut (ICS), Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Bonet Monné S] Servei d’Atenció Primària (SAP) Baix Llobregat Centre, Institut Català de la Salut (ICS), Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Canadell Vilarrasa L] Servei de Farmàcia, Hospital Universitari Joan XXIII de Tarragona, Institut Català de la Salut (ICS), Generalitat de Catalunya, Tarragona, Spain. [Cano Marron M] Servei de Farmàcia, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Carrasco Fons N] Servei de Farmàcia, Hospital de Viladecans, Institut Català de la Salut (ICS), Generalitat de Catalunya, Viladecans, Spain. [Casanovas Marfà MM] Servei de Farmàcia, Servei d’Atenció Primària (SAP) Anoia, Institut Català de la Salut (ICS), Generalitat de Catalunya, Igualada, Spain. [Chamarro Martí E] Servei de Medicina Interna, Hospital de Tortosa Verge de la Cinta, Institut Català de la Salut (ICS), Generalitat de Catalunya, Tortosa, Spain. [Cots Yago JM] Centre d’Atenció Primària La Marina, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. [Fernández Polo A] Servei de Farmàcia, Hospital Universitari Vall d'Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. [García González M] Servei de Microbiologia, Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [García Pardo G] Servei de Medicina Interna, Hospital Universitari Joan XXIII de Tarragona, Institut Català de la Salut (ICS), Generalitat de Catalunya, Tarragona, Spain. [García Vicente JA] Servei d’Atenció Primària (SAP) Barcelonès Nord i Maresme, Institut Català de la Salut (ICS), Generalitat de Catalunya, Sabadell, Spain. [Giménez Perez M] Servei de Microbiologia, Hospital Universitari Germans Trias i Pujol, Institut Català de la Salut (ICS), Generalitat de Catalunya, Badalona, Spain. [Gómez Bertomeu F] Servei de Microbiologia, Hospital Universitari Joan XXIII de Tarragona, Institut Català de la Salut (ICS), Generalitat de Catalunya, Tarragona, Spain. [Gratacós Santanach L] Servei de Farmàcia, Hospital Universitari de Girona Dr. Josep Trueta, Institut Català de la Salut (ICS), Generalitat de Catalunya, Girona, Spain. [Gudiol González C, Pujol Rojo M] Servei de Malalties Infeccioses, Hospital Universitari de Bellvitge, Institut Català de la Salut (ICS), Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Llopis Diaz MA] Laboratoris Clínics, Direcció Assistencial d’Hospitals, Centre Corporatiu, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. [Jover Sáenz A] Unitat Territorial Infecció Nosocomial i Política Antibiòtica (UTIN), Hospital Universitari Arnau de Vilanova, Institut Català de la Salut (ICS), Generalitat de Catalunya, Lleida, Spain. [Julián Ávila E] Servei de Farmàcia, Hospital de Tortosa Verge de la Cinta, Institut Català de la Salut (ICS), Generalitat de Catalunya, Tortosa, Spain. [Larrosa Escartín MN] Servei de Microbiologia, Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. [Lérida Urteaga A] Servei de Medicina Interna, Hospital de Viladecans, Institut Català de la Salut (ICS), Generalitat de Catalunya, Viladecans, Spain. [Martín Gonzalez L] Unitat de Qualitat i Medicina Preventiva, Hospital de Viladecans, Institut Català de la Salut (ICS), Generalitat de Catalunya, Viladecans, Spain. [Mòdol Deltell JM] Servei de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Institut Català de la Salut (ICS), Generalitat de Catalunya, Badalona, Spain. [Molina Lázaro A, Oms Arias M] Unitat de Coordinació i Estratègia del Medicament, Centre Corporatiu, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. [Motjé Casas M] Servei de Microbiologia, Hospital Universitari de Girona Dr. Josep Trueta, Institut Català de la Salut (ICS), Generalitat de Catalunya, Girona, Spain. [Padullés Zamora A] Servei de Farmàcia, Hospital Universitari de Bellvitge, Institut Català de la Salut (ICS), Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain. [Pérez Moreno MO] Servei de Microbiologia, Hospital de Tortosa Verge de la Cinta, Institut Català de la Salut (ICS), Generalitat de Catalunya, Tortosa, Spain. [Salgado Serrano X] Servei de Medicina Interna, Hospital Universitari de Girona Dr. Josep Trueta, Institut Català de la Salut (ICS), Generalitat de Catalunya, Girona, Spain. [Troncoso Mariño A] Àrea de Suport al Medicament i Servei de Farmàcia, Gerència Territorial de Barcelona Ciutat, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain, and Institut Català de la Salut

Subjects
personas::Grupos de Edad::adulto [DENOMINACIONES DE GRUPOS], Persons::Age Groups::Adult [NAMED GROUPS], Antibiòtics - Prescripció, Female Urogenital Diseases and Pregnancy Complications::Female Urogenital Diseases::Urologic Diseases [DISEASES], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [CHEMICALS AND DRUGS], Bacterial Infections and Mycoses::Bacterial Infections [DISEASES], enfermedades de los genitales femeninos y complicaciones del embarazo::enfermedades urogenitales femeninas::enfermedades urológicas [ENFERMEDADES], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos [COMPUESTOS QUÍMICOS Y DROGAS], infecciones bacterianas y micosis::infecciones bacterianas [ENFERMEDADES], Aparell urinari - Infeccions, Adults - Pacients
Abstract

Antibiòtics; Infeccions; Tracte urinari; Adults Antibiotics; Infections; Urinary tract; Adults Antibióticos; Infecciones; Tracto urinario; Adultos Al document s’hi aborden les principals infeccions del tracte urinari, es descriuen les recomanacions i accions a dur a terme abans de prescriure un antibiòtic i se n’estableixen criteris de tractament, seguiment i derivació.

Published
2021

11. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Author

François-Xavier Lescure, Hitoshi Honda, Robert A Fowler, Jennifer Sloane Lazar, Genming Shi, Peter Wung, Naimish Patel, Owen Hagino, Ignacio J. Bazzalo, Marcelo M. Casas, Sebastián A. Nuñez, Yael Pere, Carlos M. Ibarrola, Marco A. Solis Aramayo, Maria C. Cuesta, Andrea E. Duarte, Pablo M. Gutierrez Fernandez, Maria A. Iannantuono, Erica A. Miyazaki, Javier P. Silvio, Dario G. Scublinsky, Alessandra Bales, Daniela Catarino, Elie Fiss, Sara Mohrbacher, Victor Sato, Antonio Baylao, Adilson Cavalcante, Francini Correa, Celso A. de Andrade, Juvencio Furtado, Nelson Ribeiro Filho, Valéria Telles, Leopoldo T. Trevelin, Ricardo Vipich, Rodrigo Boldo, Paula Borges, Suzana Lobo, Graziela Luckemeyer, Luana Machado, Maysa B. Alves, Ana C. Iglessias, Marianna M. Lago, Daniel W. Santos, Hugo Chapdelaine, Emilia L. Falcone, Rahima Jamal, Me-Linh Luong, Madeleine Durand, Stephane Doucet, François-Martin Carrier, Bryan A. Coburn, Lorenzo Del Sorbo, Sharon L. Walmsley, Sara Belga, Luke Y. Chen, Allison D. Mah, Theodore Steiner, Alissa J. Wright, J. Hajek, Neill Adhikari, Robert A. Fowler, Nick Daneman, Kosar A. Khwaja, Jason Shahin, Carolina Gonzalez, Rafael Silva, Marcelo Lindh, Gabriel Maluenda, Patricia Fernandez, Maite Oyonarte, Martin Lasso, Alexandre Boyer, Didier Bronnimann, Hoang-Nam Bui, Charles Cazanave, Helene Chaussade, Arnaud Desclaux, Mailys Ducours, Alexandre Duvignaud, Denis Malvy, Lisa Martin, Didier Neau, Duc Nguyen, Thierry Pistone, Gaetane Soubrane-Wirth, Julie Leitao, Clotilde Allavena, Charlotte Biron, Sabelline Bouchez, Benjamin Gaborit, Antoine Gregoire, Paul Le Turnier, Anne-Sophie Lecompte, Raphael Lecomte, Maeva Lefebvre, Francois Raffi, David Boutoille, Pascale H. Morineau, Romain Guéry, Emmanuel Chatelus, Nathalie Dumoussaud, Renaud Felten, Florina Luca, Bernard Goichot, Francis Schneider, Marie-Caroline Taquet, Matthieu Groh, Mathilde Roumier, Mathilde Neuville, Antoine Bachelard, Valentina Isernia, F-Xavier Lescure, Bao-Chau Phung, Anne Rachline, Aurelie Sautereau, Dorothee Vallois, Yves Bleher, Delphine Boucher, Clémentine Coudon, Jean Esnault, Thomas Guimard, Sophie Leautez-Nainville, Dominique Merrien, Marine Morrier, Pauline Motte-Vincent, Romain Gabeff, Hélène Leclerc, Céline Cozic, Romain Decours, Ronan Février, Gwenhael Colin, Sophie Abgrall, Dorothee Vignes, Raluca Sterpu, Mira Kuellmar, Melanie Meersch-Dini, Raphael Weiss, Alexander Zarbock, Christiane Antony, Marc Berger, Thorsten Brenner, Christian Taube, Frank Herbstreit, Sebastian Dolff, Margarethe Konik, Karsten Schmidt, Markus Zettler, Oliver Witzke, Boris Boell, Jorge Garcia Borrega, Philipp Koehler, Thomas Zander, Fabian Dusse, Othman Al-Sawaf, Philipp Köhler, Dennis Eichenauer, Matthias Kochanek, Alexander Shimabukuro-Vornhagen, Sibylle Mellinghoff, Annika Claßen, Jan-Michel Heger, Charlotte Meyer-Schwickerath, Paul Liedgens, Katrin Heindel, Ana Belkin, Asaf Biber, Mayan Gilboa, Itzchak Levy, Vladislav Litachevsky, Galia Rahav, Anat Finesod Wiedner, Tal Zilberman-Daniels, Yonatan Oster, Jacob Strahilevitz, Sigal Sviri, Elena M. Baldissera, Corrado Campochiaro, Giulio Cavalli, Lorenzo Dagna, Giacomo De Luca, Emanuel Della Torre, Alessandro Tomelleri, Davide Bernasconi De Luca, Amedeo F. Capetti, Massimo Coen, Maria V. Cossu, Massimo Galli, Andrea Giacomelli, Guido A. Gubertini, Stefano Rusconi, Giulia J. Burastero, Margherita Digaetano, Giovanni Guaraldi, Marianna Meschiari, Cristina Mussini, Cinzia Puzzolante, Sara Volpi, Marina Aiello, Alarico Ariani, Alfredo A. Chetta, Annalisa Frizzelli, Andrea Ticinesi, Domenico Tuttolomondo, Stefano Aliberti, Francesco B. Blasi, Marta F. Di Pasquale, Sofia Misuraca, Tommaso Pilocane, Edoardo Simonetta, Alessio M. Aghelmo, Claudio Angelini, Enrico Brunetta, Giorgio W. Canonica, Michele Ciccarelli, Sara Dal Farra, Maria De Santis, Sebastian Ferri, Marco Folci, Giacomo M. Guidelli, Enrico M. Heffler, Ferdinando Loiacono, Giacomo Malipiero, Giovanni Paoletti, Rosa Pedale, Francesca A. Puggioni, Francesca Racca, Aurora Zumbo, Morihiko Satou, Tatyana Lisun, Denis Protsenko, Nikolay Rubtsov, Irina Beloglazova, Daria Fomina, Mariana Lysenko, Sofia Serdotetskova, Vitali Firstov, Ivan Gordeev, Ilia Kokorin, Ksenia Komissarova, Nina Lapochkina, Elena Luchinkina, Valentin Malimon, Sevinch Mamedguseyinova, Ksenia Polubatonova, Natalia Suvorova, Jose Arribas, Alberto M. Borobia Perez, Fernando de la Calle Prieto, Juan Carlos Figueira, Rocio Motejano Sanchez, Marta Mora-Rillo, Concepcion Prados Sanchez, Javier Queiruga Parada, Francisco Fernandez Arnalich, Maria Guerro Barrientos, Alejandro Bendala Estrada, Aranzazu Caballero Marcos, Maria E. Garcia Leoni, Rita García-Martínez, Ana María Collado, Patricia Munoz Garcia, Ana Torres do Rego, María V. Villalba García, Almudena Burrillo, Maricela Valerio Minero, Paloma Gijon Vidaurreta, Sonsoles Infante Herrero, Elena Velilla, Marina Machado, Maria Olmedo, Blanca Pinilla, Benito Almirante Gragera, Maria de la Esperanza Cañas Ruano, Sofia Contreras Medina, Alejandro Cortés Herrera, Vicenç Falcó Ferrer, Ricard Ferrer Roca, Xavier Nuvials Casals, Esteve Ribera Pascuet, Paula Suanzes Diez, Pedro Rebollo Castro, Felipe Garcia Alcaide, Alejandro Soriano, Aina Oliver Caldes, Ana González Cordón, Celia Cardozo, Lorena De la Mora Cañizo, Romina Pena López, Sandra Chamorro, Clara Crespillo-Andujar, Rosa Escudero Sanchez, Jesús Fortún-Abete, Begoña Monge-Maillo, Ana Moreno Zamora, Francesca Norman, Matilde Sanchez Conde, Sergio Serrano Villar, Pilar Vizcarra, Lescure, F. -X., Honda, H., Fowler, R. A., Lazar, J. S., Shi, G., Wung, P., Patel, N., Hagino, O., Bazzalo, I. J., Casas, M. M., Nunez, S. A., Pere, Y., Ibarrola, C. M., Solis Aramayo, M. A., Cuesta, M. C., Duarte, A. E., Gutierrez Fernandez, P. M., Iannantuono, M. A., Miyazaki, E. A., Silvio, J. P., Scublinsky, D. G., Bales, A., Catarino, D., Fiss, E., Mohrbacher, S., Sato, V., Baylao, A., Cavalcante, A., Correa, F., de Andrade, C. A., Furtado, J., Ribeiro Filho, N., Telles, V., Trevelin, L. T., Vipich, R., Boldo, R., Borges, P., Lobo, S., Luckemeyer, G., Machado, L., Alves, M. B., Iglessias, A. C., Lago, M. M., Santos, D. W., Chapdelaine, H., Falcone, E. L., Jamal, R., Luong, M. -L., Durand, M., Doucet, S., Carrier, F. -M., Coburn, B. A., Del Sorbo, L., Walmsley, S. L., Belga, S., Chen, L. Y., Mah, A. D., Steiner, T., Wright, A. J., Hajek, J., Adhikari, N., Daneman, N., Khwaja, K. A., Shahin, J., Gonzalez, C., Silva, R., Lindh, M., Maluenda, G., Fernandez, P., Oyonarte, M., Lasso, M., Boyer, A., Bronnimann, D., Bui, H. -N., Cazanave, C., Chaussade, H., Desclaux, A., Ducours, M., Duvignaud, A., Malvy, D., Martin, L., Neau, D., Nguyen, D., Pistone, T., Soubrane-Wirth, G., Leitao, J., Allavena, C., Biron, C., Bouchez, S., Gaborit, B., Gregoire, A., Le Turnier, P., Lecompte, A. -S., Lecomte, R., Lefebvre, M., Raffi, F., Boutoille, D., Morineau, P. H., Guery, R., Chatelus, E., Dumoussaud, N., Felten, R., Luca, F., Goichot, B., Schneider, F., Taquet, M. -C., Groh, M., Roumier, M., Neuville, M., Bachelard, A., Isernia, V., Phung, B. -C., Rachline, A., Sautereau, A., Vallois, D., Bleher, Y., Boucher, D., Coudon, C., Esnault, J., Guimard, T., Leautez-Nainville, S., Merrien, D., Morrier, M., Motte-Vincent, P., Gabeff, R., Leclerc, H., Cozic, C., Decours, R., Fevrier, R., Colin, G., Abgrall, S., Vignes, D., Sterpu, R., Kuellmar, M., Meersch-Dini, M., Weiss, R., Zarbock, A., Antony, C., Berger, M., Brenner, T., Taube, C., Herbstreit, F., Dolff, S., Konik, M., Schmidt, K., Zettler, M., Witzke, O., Boell, B., Garcia Borrega, J., Koehler, P., Zander, T., Dusse, F., Al-Sawaf, O., Kohler, P., Eichenauer, D., Kochanek, M., Shimabukuro-Vornhagen, A., Mellinghoff, S., Classen, A., Heger, J. -M., Meyer-Schwickerath, C., Liedgens, P., Heindel, K., Belkin, A., Biber, A., Gilboa, M., Levy, I., Litachevsky, V., Rahav, G., Finesod Wiedner, A., Zilberman-Daniels, T., Oster, Y., Strahilevitz, J., Sviri, S., Baldissera, E. M., Campochiaro, C., Cavalli, G., Dagna, L., De Luca, Giacomo., Della Torre, E., Tomelleri, A., Bernasconi De Luca, D., Capetti, A. F., Coen, M., Cossu, M. V., Galli, M., Giacomelli, A., Gubertini, G. A., Rusconi, S., Burastero, G. J., Digaetano, M., Guaraldi, G., Meschiari, M., Mussini, C., Puzzolante, C., Volpi, S., Aiello, M., Ariani, A., Chetta, A. A., Frizzelli, A., Ticinesi, A., Tuttolomondo, D., Aliberti, S., Blasi, F. B., Di Pasquale, M. F., Misuraca, S., Pilocane, T., Simonetta, E., Aghelmo, A. M., Angelini, C., Brunetta, E., Canonica, G. W., Ciccarelli, M., Dal Farra, S., De Santis, M., Ferri, S., Folci, M., Guidelli, G. M., Heffler, E. M., Loiacono, F., Malipiero, G., Paoletti, G., Pedale, R., Puggioni, F. A., Racca, F., Zumbo, A., Satou, M., Lisun, T., Protsenko, D., Rubtsov, N., Beloglazova, I., Fomina, D., Lysenko, M., Serdotetskova, S., Firstov, V., Gordeev, I., Kokorin, I., Komissarova, K., Lapochkina, N., Luchinkina, E., Malimon, V., Mamedguseyinova, S., Polubatonova, K., Suvorova, N., Arribas, J., Borobia Perez, A. M., de la Calle Prieto, F., Figueira, J. C., Motejano Sanchez, R., Mora-Rillo, M., Prados Sanchez, C., Queiruga Parada, J., Fernandez Arnalich, F., Guerro Barrientos, M., Bendala Estrada, A., Caballero Marcos, A., Garcia Leoni, M. E., Garcia-Martinez, R., Collado, A. M., Munoz Garcia, P., Torres do Rego, A., Villalba Garcia, M. V., Burrillo, A., Valerio Minero, M., Gijon Vidaurreta, P., Infante Herrero, S., Velilla, E., Machado, M., Olmedo, M., Pinilla, B., Almirante Gragera, B., Canas Ruano, M. D. L. E., Contreras Medina, S., Cortes Herrera, A., Falco Ferrer, V., Ferrer Roca, R., Nuvials Casals, X., Ribera Pascuet, E., Suanzes Diez, P., Rebollo Castro, P., Garcia Alcaide, F., Soriano, A., Oliver Caldes, A., Gonzalez Cordon, A., Cardozo, C., De la Mora Canizo, L., Pena Lopez, R., Chamorro, S., Crespillo-Andujar, C., Escudero Sanchez, R., Fortun-Abete, J., Monge-Maillo, B., Moreno Zamora, A., Norman, F., Sanchez Conde, M., Serrano Villar, S., and Vizcarra, P.

Subjects
Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Critical Care, International Cooperation, Population, Antibodies, Monoclonal, Humanized, Placebo, Severity of Illness Index, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Intensive care, Severity of illness, medicine, Clinical endpoint, Humans, Immunologic Factors, 030212 general & internal medicine, Mortality, education, Respiratory Distress Syndrome, education.field_of_study, Dose-Response Relationship, Drug, SARS-CoV-2, business.industry, Hazard ratio, COVID-19, Articles, Middle Aged, Receptors, Interleukin-6, Sarilumab, Treatment Outcome, 030228 respiratory system, Female, Drug Monitoring, Cytokine Release Syndrome, business
Abstract

Summary Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding Sanofi and Regeneron Pharmaceuticals.

Published
2021

12. Long-term follow-up of jaw osteomyelitis associated with bisphosphonate use in a tertiary-care center.

Author

Pigrau-Serrallach C, Cabral-Galeano E, Almirante-Gragera B, Sordé-Masip R, Rodriguez-Pardo D, Fernandez-Hidalgo N, Larrosa-Escartín N, Bescos-Atín S, and Pahissa-Berga A

Subjects
Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Osteomyelitis diagnosis, Osteomyelitis therapy, Retrospective Studies, Tertiary Care Centers, Time Factors, Bone Density Conservation Agents adverse effects, Diphosphonates adverse effects, Jaw, Osteomyelitis chemically induced, Osteomyelitis microbiology
Abstract

Objectives: This study reviews our experience in bisphosphonate-associated jaw osteomyelitis (BJOM), focusing on the incidence, etiology, treatment, and long-term outcome., Methods: Retrospective review of the clinical histories adult patients diagnosed with BJOM (1995-2008) in a tertiary hospital., Results: BJOM was found in 30 of 132 (22.7%) consecutive patients with jaw osteomyelitis. The percentage of BJOM cases increased from 8.7% (4/46) in 1995-2005 to 30.2% (26/86) in 2005-2008. Symptoms appeared in a median of 2.5 years after intravenous use, and 4.5 years after oral exposure. Viridans group streptococci were isolated in 83.3% of cases. Actinomyces spp. was found in 16 (39.0%) of 41 bone histologies. All included patients received a median of 6 months of appropiate antibiotic therapy and a surgical procedure (debridament and/or sequestrectomy). Thirteen of 27 cases (48.1%) with long-term follow-up (median 22 months, IQR 25-75 17-28) failed. Clinical failure defined as, persistent infection or relapse, was more frequent in patients receiving intravenous than oral bisphosphonates (11/16 [68.8%] vs. 2/11 [18.2%]; P < .05) and in cases with Actinomyces spp. (7/10 [70.0%] vs6/17 [35.3%]; P = .08)., Conclusions: Bisphosphonate therapy is now a frequent cause of JO. BJOM is difficult to cure and relapses are common, particularly in patients exposed to intravenous bisphosphonates., (Copyright © 2012 Elsevier España, S.L. All rights reserved.)

Published
2014
Full Text
View/download PDF

13. [Home intravenous antimicrobial therapy in multi-drug resistant microorganism infections].

Author

Pérez-López J, Pardos-Gea J, San José Laporte A, Almirante Gragera B, Marian Oltean D, and Vilardell Tarrés M

Subjects
Drug Resistance, Multiple, Bacterial, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Anti-Infective Agents administration & dosage, Bacterial Infections drug therapy, Home Care Services
Abstract

Background: Although home intravenous antimicrobial infusion therapy (HIVAIT) has proved its safety and efficacy in a great number of common infections, there are few published studies about its role in the treatment of infections caused by multi-drug resistant microorganisms. Our objectives are to study clinical and epidemiological characteristics of patients with multi-drug resistant microorganism infections treated with HIVAIT, and its usefulness in this type of infections., Methods: We analyzed all patients diagnosed of infections requiring HIVAIT and admitted to our Hospital at Home Unit (HHU) from March 2007 to February 2010. Subjects were divided into two groups: patients with multi-drug resistant microorganism infections as a study group, and the remaining patients as a control group., Results: A total of 487 patients were included, 82 in the study group. Comorbidity and physical dependence were higher in this group than in the control group (p=0.000 and p=0.002 respectively). The majority of patients were discharged because of a satisfactory clinical evolution. However, 17 (20.7%) patients in the study group required readmission to hospital during treatment and another 22 (26.8%) were re-admitted to hospital 3 months after discharge from HHU. There were significant differences between the results from the control group in clinical readmissions., Conclusions: Patients with multi-drug resistant microorganism infections and HIVAIT have higher comorbidity, physical dependence, and frequency of hospital readmissions. However, HIVAIT is useful in this kind of infections if the patients are appropriately selected., (Copyright © 2011 Elsevier España, S.L. All rights reserved.)

Published
2012
Full Text
View/download PDF

15. [Empiric treatment of community-acquired pneumonia].

Author

Fálco Ferrer V, Almirante Gragera B, and Pahissa Berga A

Subjects
Community-Acquired Infections microbiology, Drug Therapy, Combination therapeutic use, Humans, Pneumonia, Bacterial microbiology, Practice Guidelines as Topic, Anti-Bacterial Agents therapeutic use, Community-Acquired Infections drug therapy, Pneumonia, Bacterial drug therapy
Published
2004
Full Text
View/download PDF

16. [Methicillin-resistant Staphylococcus aureus infection in a geriatric unit for acutely ill].

Author

Selva O'Callaghan A, San José Laporte A, Almirante Gragera B, and Vilardell Tarrés M

Subjects
Aged, Aged, 80 and over, Aminoglycosides, Anti-Bacterial Agents therapeutic use, Female, Humans, Male, Methicillin Resistance, Mupirocin therapeutic use, Staphylococcal Infections mortality, Teicoplanin therapeutic use, Vancomycin therapeutic use, Methicillin pharmacology, Penicillins pharmacology, Staphylococcal Infections drug therapy, Staphylococcus aureus drug effects
Published
1998

17. [Prosthetic valve endocarditis].

Author

Almirante Gragera B, Tornos Mas MP, and Soler-Soler J

Subjects
Echocardiography, Electrocardiography, Endocarditis, Bacterial diagnosis, Endocarditis, Bacterial therapy, Humans, Replantation, Risk Factors, Time Factors, Endocarditis, Bacterial etiology, Heart Valve Prosthesis adverse effects, Prosthesis-Related Infections
Abstract

Infective endocarditis occurs in 4% of prosthetic valve carriers. The infection is related to both the injured endocardium and circulating microorganisms. Early prosthetic endocarditis, occurring in the first 12 months after valvular surgery is mainly caused by staphylococci, and late prosthetic endocarditis has a similar etiology as native valve endocarditis. Clinical manifestations of early cases are due to both bacteremia and prosthetic malfunction. In late cases the clinical picture is similar to native valve disease. Mortality in prosthetic endocarditis remains high, especially in early cases, despite combined medical and surgical treatment.

Published
1998

19. [Pneumococcal infection in the cirrhotic patient].

Author

Almirante Gragera B

Subjects
Animals, Anti-Bacterial Agents therapeutic use, Bacterial Vaccines, Humans, Immunocompromised Host, Incidence, Liver Cirrhosis immunology, Pneumococcal Infections drug therapy, Pneumococcal Infections epidemiology, Pneumococcal Infections prevention & control, Rats, Risk Factors, Liver Cirrhosis complications, Pneumococcal Infections complications
Published
1996

20. [Infection and urinary catheterization].

Author

Almirante Gragera B

Subjects
Bacteriuria etiology, Bacteriuria microbiology, Humans, Urethra microbiology, Urinary Tract Infections microbiology, Urinary Catheterization adverse effects, Urinary Tract Infections etiology
Published
1991

21. [The clinician and cytomegalovirus infections].

Author

Almirante Gragera B and Pahissa Berga A

Subjects
Acquired Immunodeficiency Syndrome complications, Acquired Immunodeficiency Syndrome diagnosis, Antibodies, Monoclonal, Antibodies, Viral blood, Cytomegalovirus genetics, Cytomegalovirus immunology, Cytomegalovirus Infections complications, DNA, Viral genetics, Humans, Nucleic Acid Hybridization, Opportunistic Infections complications, Opportunistic Infections diagnosis, Transplantation Immunology immunology, Cytomegalovirus Infections diagnosis
Published
1990

22. [Meningitis caused by Staphylococcus aureus. Analysis of 16 cases].

Author

Falcó Ferrer V, Almirante Gragera B, Pahissa Berga A, Gasser I, Fernández Pérez F, and Martínez Vázquez JM

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Male, Meningitis cerebrospinal fluid, Middle Aged, Meningitis etiology, Postoperative Complications etiology, Staphylococcal Infections
Abstract

During the period between 1982 and 1987, 16 cases of meningitis due to Staphylococcus aureus were diagnosed. Nine patients (56%) had undergone a previous neurosurgical operation and 5 of them were carriers of a cerebrospinal fluid (CSF) shunt. Seven patients (44%) had spontaneous meningitis. Fever and meningeal signs were the most common clinical findings. 50% of patients were comatose. The Gram stain of CSF showed Gram positive cocci in 7 cases. Blood cultures were positive in all patients with spontaneous meningitis and negative in the neurosurgical group. Overall mortality rate was 37.5%, and it was lower in the neurosurgical group than in the spontaneous meningitis. Other factors associated with a poor outcome were advanced age, bacteremia and septic shock.

Published
1990

23. [Anemia and primary amyloidosis].

Author

Almirante Gragera B and Mirada Canals A

Subjects
Aged, Female, Hemorrhagic Disorders etiology, Humans, Amyloidosis complications, Anemia etiology
Published
1985

Catalog

Books, media, physical & digital resources
See catalog results